.jpeg)
2025-10-19 11:44:20
2025-10-19 11:44:20
Talatuzumab is a DLL3/CD3 bispecific antibody drug developed by the American company Amgen. It can guide T cells directly to abnormal cells, activate T cells and prompt them to release cytotoxic substances, thereby killing abnormal cells. Understanding drug prices, treatment costs, and efficacy performance can help patients make financial plans and treatment expectations. This article will introduce in detail the price of a single box of talatumumab, the cost of a complete course of treatment, and clinical efficacy data to provide readers with a comprehensive medication reference.
2025-10-19 11:44:20
Talatuzumab is an innovative bispecific antibody drug developed by Amgen of the United States for the treatment of extensive-stage small cell lung cancer (ES-SCLC) that has progressed after platinum-containing chemotherapy.
2025-10-19 11:44:20
